A Study of Gantenerumab in Participants With Mild Alzheimer Disease

NCT02051608 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

389

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Placebo
DRUG: Gantenerumab

Sponsor

Hoffmann-La Roche